A052 |
Nirsevimab Biosimilar (Anti-RSV Reference Antibody)
Featured
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections. |
|
A053 |
Aselizumab Biosimilar (Anti-L-selectin Reference Antibody)
Featured
|
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma. |
|
A054 |
Raxibacumab Biosimilar(Anti-PA Reference Antibody)
Featured
|
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research. |
|
A055 |
Afelimomab Biosimilar (Anti-TNFSF2 / TNFa Reference Antibody)
Featured
|
Afelimomab (MAK 195F) is an anti-tumor necrosis factor F(ab')2 monoclonal antibody fragment. Afelimomab can be used for the research of sepsis. |
|
A056 |
Agensys patent anti-158P1D7 Biosimilar (Anti-158P1D7 Reference Antibody)
Featured
|
|
|
A057 |
Numab patent anti-HSA Biosimilar(Anti-Albumin Reference Antibody)
Featured
|
|
|
A058 |
Birtamimab Biosimilar (Anti-Amyloid Alpha Reference Antibody)
Featured
|
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis. |
|
A059 |
Mirzotamab Biosimilar (Anti-B7-H3 / CD276 Reference Antibody)
Featured
|
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC). |
|
A060 |
Cantuzumab Biosimilar (Anti-CanAg Reference Antibody)
Featured
|
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493). |
|
A061 |
VLST-002 Biosimilar (Anti-CCL5 / RANTES Reference Antibody)
Featured
|
|
|
A062 |
R707 Biosimilar (Anti-CCR7 / CD197 Reference Antibody)
Featured
|
|
|
A063 |
Ofatumumab Biosimilar (Anti-CD20 Reference Antibody)
Featured
|
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes. |
|
A064 |
Genefrontier patent anti-CD69 Biosimilar (Anti-CD69 Reference Antibody)
Featured
|
|
|
A065 |
KHK-2898 Biosimilar (Anti-CD98 Reference Antibody)
Featured
|
|
|
A066 |
CergutuzumAb Biosimilar (Anti-CEACAM5 / CEA / CD66e Reference Antibody)
Featured
|
|
|
A067 |
Immunomedics patent anti-CEACAM5 (Class III) Biosimilar (Anti-CEACAM5 / CEA / CD66e Reference Antibody)
Featured
|
|
|
A068 |
IMAB027 Biosimilar (Anti-CLDN6 Reference Antibody)
Featured
|
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6+ ovarian and testicular cancer cell lines. |
|
A069 |
AB1-11 Biosimilar (Anti-CLDN6 Reference Antibody)
Featured
|
|
|
A070 |
IM-301 Biosimilar (Anti-CLDN6 Reference Antibody)
Featured
|
|
|
A071 |
lendalizumab Biosimilar (Anti-Complement C5 Reference Antibody)
Featured
|
|
|
A072 |
Nurulimab Biosimilar (Anti-CTLA-4 / CD152 Reference Antibody)
Featured
|
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma. |
|
DC66645 |
Epilactose
Featured
|
|
|
DC66646 |
Dinotefuran UF
Featured
|
Dinotefuran UF is the deuterium labeled γ-Tocotrienol. γ-Tocotrienol is an active form of vitamin E |
|
DC66647 |
ICA-1S
Featured
|
ICA-1S is a potent, specific inhibitor of Protein Kinase C-iota (PKC-ι), does not inhibit PKC-ζ, the closely related atypical PKC family member. |
|
DC60638 |
Acid-degradable PEG Lipid (ADP-2k)
Featured
|
Acid-degradable PEG Lipid (ADP) composed of polyethylene glycol lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo. |
|
DC60639 |
Acid-degradable Anionic Lipid (ADA)
Featured
|
Acid-degradable Anionic Lipid (ADA) composed of anionic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo. |
|
DC60640 |
LI-3948
Featured
|
LI-3948 is a blood-brain barrier penetrant inositol hexakisphosphate kinase (IP6K) inhibitor with IC50 of 16 nM and brain/plasma ratio of 1.3, respectively. |
|
DC66648 |
CP-LC-1143
Featured
|
Lipid CP-LC-1143 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity. |
|
DC66651 |
CP-LC-0743
Featured
|
Lipid CP-LC-0743 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity. |
|
A073 |
Antitope patent anti-CTLA4 Biosimilar (Anti-CTLA-4 / CD152 Reference Antibody)
Featured
|
|
|